These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 15041274)
41. Anti-factor Xa plasma levels in pregnant women receiving low molecular weight heparin thromboprophylaxis. Fox NS; Laughon SK; Bender SD; Saltzman DH; Rebarber A Obstet Gynecol; 2008 Oct; 112(4):884-9. PubMed ID: 18827132 [TBL] [Abstract][Full Text] [Related]
42. Fluctuations in anti-factor Xa levels with therapeutic enoxaparin anticoagulation in pregnancy. Friedrich E; Hameed AB J Perinatol; 2010 Apr; 30(4):253-7. PubMed ID: 19829297 [TBL] [Abstract][Full Text] [Related]
44. How useful is the monitoring of (low molecular weight) heparin therapy by anti-Xa assay? A laboratory perspective. Favaloro EJ; Bonar R; Aboud M; Low J; Sioufi J; Wheeler M; Lloyd J; Street A; Marsden K; Lab Hematol; 2005; 11(3):157-62. PubMed ID: 16174600 [TBL] [Abstract][Full Text] [Related]
45. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment. Kruse MW; Lee JJ Am Heart J; 2004 Oct; 148(4):582-9. PubMed ID: 15459586 [TBL] [Abstract][Full Text] [Related]
46. The utility of thromboelastography in monitoring low molecular weight heparin therapy in the coronary care unit. White H; Sosnowski K; Bird R; Jones M; Solano C Blood Coagul Fibrinolysis; 2012 Jun; 23(4):304-10. PubMed ID: 22473047 [TBL] [Abstract][Full Text] [Related]
47. Monitoring of enoxaparin level using citrated clotting time during percutaneous coronary intervention. Díez JG; Cheong BY; O'Meallie LP; Alt EU J Interv Cardiol; 2004 Oct; 17(5):307-13. PubMed ID: 15491334 [TBL] [Abstract][Full Text] [Related]
48. Enoxaparin dosage adjustment in patients with severe renal failure: antifactor xa concentrations and safety. Lachish T; Rudensky B; Slotki I; Zevin S Pharmacotherapy; 2007 Oct; 27(10):1347-52. PubMed ID: 17896889 [TBL] [Abstract][Full Text] [Related]
49. Retrospective evaluation of antithrombin III supplementation in neonates and infants receiving enoxaparin for treatment of thrombosis. Corder A; Held K; Oschman A Pediatr Blood Cancer; 2014 Jun; 61(6):1063-7. PubMed ID: 24375987 [TBL] [Abstract][Full Text] [Related]
50. Central venous catheter sampling of low molecular heparin levels: an approach to increasing result reliability. Bauman ME; Belletrutti M; Bauman ML; Massicotte MP Pediatr Crit Care Med; 2012 Jan; 13(1):1-5. PubMed ID: 21317677 [TBL] [Abstract][Full Text] [Related]
51. Early postoperative use of unfractionated heparin or enoxaparin is associated with increased surgical re-exploration for bleeding. Jones HU; Muhlestein JB; Jones KW; Renlund DG; Bair TL; Bunch TJ; Horne BD; Lappé DL; Anderson JL; Doty DB Ann Thorac Surg; 2005 Aug; 80(2):518-22. PubMed ID: 16039196 [TBL] [Abstract][Full Text] [Related]
52. Degree of anticoagulation after one subcutaneous and one subsequent intravenous booster dose of enoxaparin: implications for patients with acute coronary syndromes undergoing early percutaneous coronary intervention. Levine GN; Ferrando T J Thromb Thrombolysis; 2004 Jun; 17(3):167-71. PubMed ID: 15353913 [TBL] [Abstract][Full Text] [Related]
53. The activated clotting time (ACT) can be used to monitor enoxaparin and dalteparin after intravenous administration. Cavusoglu E; Lakhani M; Marmur JD J Invasive Cardiol; 2005 Aug; 17(8):416-21. PubMed ID: 16079447 [TBL] [Abstract][Full Text] [Related]
54. Heparin monitoring during cardiopulmonary bypass surgery using the one-step point-of-care whole blood anti-factor-Xa clotting assay heptest-POC-Hi. Hellstern P; Bach J; Simon M; Saggau W J Extra Corpor Technol; 2007 Jun; 39(2):81-6. PubMed ID: 17672188 [TBL] [Abstract][Full Text] [Related]
55. Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel. Sabatine MS; Morrow DA; Dalby A; Pfisterer M; Duris T; Lopez-Sendon J; Murphy SA; Gao R; Antman EM; Braunwald E; J Am Coll Cardiol; 2007 Jun; 49(23):2256-63. PubMed ID: 17560290 [TBL] [Abstract][Full Text] [Related]
56. The anticoagulant activity of enoxaparin sodium during on-line hemodiafiltration and conventional hemodialysis. Sombolos KI; Fragia TK; Gionanlis LC; Veneti PE; Bamichas GI; Fragidis SK; Georgoulis IE; Natse TA Hemodial Int; 2009 Jan; 13(1):43-7. PubMed ID: 19210277 [TBL] [Abstract][Full Text] [Related]
57. The pharmacokinetics of enoxaparin do not correlate with its pharmacodynamic effect in patients receiving dialysis therapies. Brophy DF; Carr ME; Martin EJ; Venitz J; Gehr TW J Clin Pharmacol; 2006 Aug; 46(8):887-94. PubMed ID: 16855073 [TBL] [Abstract][Full Text] [Related]
58. Comparison of activated clotting times obtained using Hemochron and Medtronic analysers in patients receiving anti-thrombin therapy during cardiac catheterisation. Chia S; Van Cott EM; Raffel OC; Jang IK Thromb Haemost; 2009 Mar; 101(3):535-40. PubMed ID: 19277416 [TBL] [Abstract][Full Text] [Related]
59. Enoxaparin use in the neonatal intensive care unit: experience over 8 years. Malowany JI; Knoppert DC; Chan AK; Pepelassis D; Lee DS Pharmacotherapy; 2007 Sep; 27(9):1263-71. PubMed ID: 17723080 [TBL] [Abstract][Full Text] [Related]
60. Characterisation of persistent anti-Xa activity following administration of the low molecular weight heparin enoxaparin sodium (Clexane). Brieger D; Dawes J Thromb Haemost; 1994 Aug; 72(2):275-80. PubMed ID: 7831665 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]